Vanguard Group Inc Seagen Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $1.03 Million - $1.16 Million	5,384 Added 0.04%	13,321,042 $2.83 Billion
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $27.7 Million - $30.5 Million	147,689 Added 1.12%	13,315,658 $2.56 Billion
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $28.4 Million - $45.3 Million	222,891 Added 1.72%	13,167,969 $2.67 Billion
Q4 2022 Feb 10, 2023	BUY	$117.37 - $139.17 $33.1 Million - $39.2 Million	281,926 Added 2.23%	12,945,078 $1.66 Billion
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $23 Million - $30.6 Million	170,001 Added 1.36%	12,663,152 $1.73 Billion

Q2 2022 Aug 12, 2022	BUY	$108.81 - $179.33 $23.3 Million - $38.4 Million	213,995 Added 1.74%	12,493,151 $2.21 Billion
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $16.6 Million - $22 Million	139,117 Added 1.15%	12,279,156 $1.77 Billion
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $9.03 Million - $12.1 Million	63,371 Added 0.52%	12,140,039 $1.88 Billion
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $20.1 Million - $24 Million	141,110 Added 1.18%	12,076,668 $2.05 Billion
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $1.61 Billion - $1.92 Billion	11,935,558 New	11,935,558 $1.88 Billion

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.